Abstract: The present invention relates to new methods for the purification of Fc-peptide fusion protein (peptibodies) derived from inclusion bodies after prokaryotic expression. In particular, it relates to chromatographic methods of the fusion peptides after refolding and dimerization comprising affinity capture, intermediate and polishing chromatographies. These methods facilitate the decrease of product-related impurities, such as sulfide variants or charge variants of the Fc-peptide fusion proteins in the final product. In addition, the present invention relates to specific conditions and selected buffers avoiding aggregation, precipitation, and degradation of the Fc-peptide fusion proteins. Finally, the methods of the present invention result in a formulated pharmaceutical composition or a pre-stage pharmaceutical composition containing an Fc-peptide fusion protein of high purity.

Abstract: The invention provides for an in vitro method for producing capsular polysaccharides of Neisseria meningitidis. The invention also provides capsular polysaccharides obtainable by the methods described herein. The capsular polysaccharides comprise capsular polysaccharide specific for Neisseria meningitidis serogroups W-135, Y, X and A. Also encompassed are chimeric capsular polysaccharides comprising or composed of CPS of Neisseria meningitidis serogroups Y/W-135, W-135/Y, B/Y, C/Y, B/W-135, C/W-135, B/Y/W-135, C/Y/W-135, B/W-135/Y, C/W-135/Y. X/A or A/X. The invention also provides for the use of these capsular polysaccharides foi as pharmaceuticals, particularly as vaccines and/or diagnostics.